We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Nephron-Sparing Surgery Possible When Treating Renal Cancer

By HospiMedica staff writers
Posted on 09 Jan 2008
Nephron-sparing surgery is a safe alternative to radical nephrectomy in selected patients with locally advanced renal cell carcinoma, according to a new study.

Researchers at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) retrospectively studied data on 567 patients treated with radical nephrectomy and 34 who underwent the nephron-sparing procedure. More...
Indications for this approach included a solitary kidney and chronic renal insufficiency. The patients were followed for a mean of 43.4 months.

The researchers found that there was disease recurrence in 29.9% of the radical nephrectomy group at a median of 13.2 months; in the sparing group, on the other hand, the corresponding proportion was 12% at a median of 24.2 months, and there were no local recurrences in these patients. However, 9% of the patients experienced procedure-related complications, compared to only 2.9% in the radical nephrectomy group. Overall outcomes were comparable, with apparently similar intraoperative blood loss, surgery duration, and hospital stay. The study was published in the December 2007 issue of the British Journal of Urology (BJU) International.

"Locally advanced renal cell carcinoma does not preclude consideration of nephron-sparing approaches,” said lead author Christopher G. Wood, M.D., an associate professor of urology and cancer biology. "Tumor size or even, in some cases, stage, is not the most important predictor of success in partial nephrectomy, but rather tumor location.”

The researchers concluded that the nephron-sparing technique should be extended to all patients in whom complete local excision of the tumor with preservation of the functional renal remnant is technically feasible.


Related Links:
University of Texas MD Anderson Cancer Center

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.